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Chase Contri SRNA
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Introduction
Although very rare, occurring one out of every 100,000
anesthesia cases, malignant hyperthermia is a
hypermetabolic disorder that anesthesia providers screen
and interrogate patients prior to every case they are
administering anesthesia. Many research studies about
anesthesia induced malignant hyperthermia have explored
new methods of testing for the genetic susceptibility for
malignant hyperthermia and into hospital based protocols
when a patient starts to show the signs and symptoms of
the metabolic disorder. This new knowledge and
understanding has decreased patient mortality of
anesthesia induced malignant hyperthermia from eighty
percent to five percent over the past three decades
(Rosenberg et al, 2007).

PATHOPHYSIOLOGY
Malignant hyperthermia is a hypermetabolic disorder
caused by mutation of the ryanodine receptor. More
specifically it deals with the ryanodine receptor located
on the major regulatory calcium release channel of the
sarcoplasmic reticulum of skeletal muscle, known as the
RYR1 receptor (Hines & Marschall, 2012). This mutation
causes an excessive release of calcium from the
sarcoplasmic reticulum when triggered that leads to
sustained muscle contraction. The release of calcium is
much more abundant compared to the body’s abilities to
remove the calcium from the muscles myoplasm. This
causes an increased metabolic state that increases
oxygen consumption, increases carbon dioxide
production, increases heat production, increases
anaerobic metabolism, and decreases ATP stores.
Calcium is removed and pumped back into the
sarcoplasmic reticulum by ATP. ATP stores are depleted
due to exhaustion of attempting to replace the
abundance of calcium back into the sarcoplasmic
reticulum and the binding of calcium to muscle’s
troponin to elicit contraction. When ATP stores are
depleted and oxygen can no longer be utilized, anaerobic
metabolism takes place leading an acidotic and
potentially fatal state.

Preoperative
Evaluation
Providers need to determine who
is susceptible to this disorder in
order to prevent malignant from
occurring to begin with.
Malignant hyperthermia is an
inherited genetic disorder and is
considered an autosomal
dominant trait. Being autosomal
dominant means that only one
parent can carry the gene and still
pass it along to their offspring.
Incidence of this gene is 1/10,000
(Anderson-Pompa et al, 2008).
A detailed pre-operative
assessment could possibly reveal a
family history of the disorder
which would warrant further preoperative evaluation and
susceptibility to malignant
hyperthermia. To determine
susceptibility, a patient could have
genome testing done to see if they
have the trait or undergo a
caffeine-halothane contracture
test (CHCT).
Caffeine Halothane Contracture
Test
•

CHCT have been shown to be
97%-99% sensitive for
malignant hyperthermia
(Rosenberg, Antognini, &
Muldoon, 2002). The CHCT
disadvantages include a
small outpatient surgery
required for a muscle biopsy,
only six locations are present
in the United States that
provides the test, and it is
expensive.

Genome Testing
•

Figure 1. Mutation of RY1 receptor causes abundant release
of calcium from sarcoplasmic reticulum that leads to a
hypermetabolic state.

Genome testing is considered
less invasive and more
convenient but only detects
thirty percent of people at
risk (Anderson-Pompa et al,
2008).

Signs and Symptoms

Anesthesia Triggers
Halogenated Agents
•
•
•
•
•

Depolarizing Muscle Relaxants

Table 1. Early and Late S/S of Malignant Hyperthermia
Malignant hyperthermia can be a difficult disorder to diagnosis while a patient is in the
anesthetized state. An anesthetist must be knowledgeable of the early and late signs and
symptoms of malignant hyperthermia. Early signs and symptoms can be vague and subtle at
first and resemble side effects of the rapid and increased calcium release. The first sign of
early progression of malignant hyperthermia is hypercarbia. Hypercarbia can be defined as
carbon dioxide level above 45 mmHg. This can be measured by an arterial blood gas analysis
or through Capnography. The increase in carbon dioxide is secondary to increase in oxygen
consumption. When the hypercarbia is present, a patient will become tachypneic to
compensate for the increase in carbon dioxide. Tachypnea will not be present with a patient
who is in a paralytic state as during some surgical cases. In this case carbon dioxide
monitoring will be crucial. Tachycardia is another early sign of malignant hyperthermia.
Tachycardia is present due to the increasing hypoxia, hypercarbia, sympathetic stimulation,
and catecholamine release that occur during this hypermetabolic state. Muscle rigidity can
also be used as an early sign and symptom of malignant hyperthermia due to the sustained
muscle contraction from the release of calcium. Masseter and extremity muscles are the
most common sites for increased rigidity during progressing malignant hyperthermia.
Muscle rigidity will still occur in these locations even if a patient has received neuromuscular
blocking drugs (Glahn et al, 2010).
Late signs and symptoms can be more detrimental to the patient as it reflects anaerobic
metabolism and deterioration. A patient can become extremely acidotic during a malignant
hypertension crisis. Metabolic acidosis can ensue due to an over production of lactic acidosis
due to anaerobic metabolism and cellular hypoxia. Systemic pH can drop dramatically due to
a combination of hypercarbia and lactic acid production. Serial arterial blood gasses need to
be analyzed during a malignant hyperthermia crisis to monitor the disease state. As the
patient becomes increasingly acidotic, cells will try to regulate the abundance of hydrogen
ions through the exchange of potassium. As a result a patient will become hyperkalemic
causing cardiac arrhythmias. Hyperthermia typically is one of the latest symptoms that
develop during a malignant hyperthermia episode. Hyperthermia occurs due to a significant
amount of heat production during sustained muscle contraction and increased ATP
phosphorylation. During a malignant hyperthermia crisis, temperatures can rise 1 degree
Celsius every five minutes and can exceed 43 degrees Celsius (Nagelhout & Plaus, 2014).
If left untreated or identified too late, malignant hyperthermia can lead to overwhelming cell
death, severe rhabdomyolysis, and life threatening disseminated intravascular coagulation
(DIC). Rhabdomyolysis is caused by increase in muscle breakdown and death and the
release of myoglobin into the bloodstream. The increase in free myoglobin can cause acute
kidney injury or failure due to renal tubule blockage. DIC can occur in the late stages of a
malignant hyperthermia crisis mainly due to profound hyperthermia. Hyperthermia causes
DIC due to a destruction and instability of clotting proteins and when developed, leads to
poor outcome for the patient. When DIC has develop during malignant hyperthermia,
cardiac arrest is fifty times more prevalent and death is ninety times more likely to occur
(Barash et al, 2013).

Desflurane
Sevoflurane
Isoflurane
Halothane
Nitrous Oxide is NOT
considered a triggereing agent
and is safe to use for someone
susceptible for malignant
hyperthermia.

•

Succinylcholine

Onset of malignant hyperthermia, after
exposure to these agents, occurs commonly
within sixty minutes. Some reports have
shown a delay of six hours to the occurrence
of malignant hyperthermia with the use of
Desflurane and Sevoflurane (Hopkins,
2000).
When a patient has been determined to be at
high risk for malignant hyperthermia either
from pre-operative testing or previous
malignant hyperthermia reaction, a safe and
preventative anesthesia plan is developed by
the anesthesia provider and nurse. Steps
and interventions including in this plan
include avoidance of the use of halogenated
agents such as Desflurane, Isoflurane,
Sevoflurane, and Halothane. Nitrous Oxide
has been proven to not be a trigger for
malignant hyperthermia and is considered
safe. There must also be avoidance of the
use of the depolarizing muscle relaxant
Succinylcholine. The use of regional or total
intravenous anesthesia (TIVA) is safe
anesthetic plans for patients susceptible to
malignant hyperthermia. Many institutions
have anesthesia machines designated
specifically for susceptible malignant
hyperthermia patients that have not had any
volatile agents that could trigger a malignant
hyperthermia response. If an institution
does not have such a machine, an anesthesia
machine being used on a susceptible patient
must have oxygen ran though it for a
minimum of ten minutes at a rate of ten
liters per minutes to ensure all volatile
agents have been flushed out. Vigilant
monitoring of these patients is imperative to
ensure a reaction does not occur or if one
does, it can be treated promptly
(Butterworth, Mackey, & Wasnick, 2013).

Treatment
The first step is being able to
recognize and determine that the
patient is undergoing a reaction
and to call for help to get the
entire medical team present and
aware of the situation. All
potential triggers must be
eliminated and removed from the
patient. Dantrolene will be given
to the patient to reverse the
progression of malignant
hyperthermia. Dantrolene is
skeletal muscle relaxant by the
mechanism of inhibiting calcium
release from the sarcoplasmic
reticulum. By inhibiting calcium
release, the progression of
malignant hyperthermia can be
ceased. The use of Dantrolene for
the treatment of malignant
hyperthermia has decreased
patient mortality from 70% to 5%.
Dantrolene is given intravenously
at a dose of 2.5mg/kg to a max
dose of 10mg/kg until termination
of malignant hyperthermia crisis.
Redosing of dantrolene is done
every six hours for 24 hours to
prevent reoccurrence of the
disease process at a dose of 1-2
mg/kg. Along with
pharmacological intervention for
reversing malignant hyperthermia
process by decreasing calcium
release, treatment and
interventions can be done to help
control the symptoms of
malignant hyperthermia;
hypercarbia, hyperthermia,
acidosis, hyperkalemia, and
arrhythmias. (Musselman and
Saely, 2013).
Conclusion
Extensive and detailed preoperative assessment must be
obtained to determine a patient’s
susceptibility of the disease in
order to determine a safe
anesthetic plan to decrease or
eliminate risk of malignant
hyperthermia crisis. If a crisis
does occur, the ability to recognize
malignant hyperthermia will lead
to faster treatment and
intervention and decreased
morbidity and mortality. The use
and knowledge of different forms
of treatment will aid and help
provide the best possible outcome
for the patient in the end.
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